Breaking News Instant updates and real-time market news.

KMX

CarMax

$59.61

-1.15 (-1.89%)

, SNAP

Snap

$18.08

-0.77 (-4.08%)

08:45
06/12/17
06/12
08:45
06/12/17
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: CarMax (KMX) 0.79% +0.07, Snap Inc. (SNAP) 38.40% +0.05, SPDR S&P Oil and Gas Exploration and Production (XOP) 1.22% +0.02, Restoration Hardware (RH) 10.36% +0.01, Energy Sector SPDR (XLE) 0.49% +0.01, and CIT Group (CIT) 1.00% +0.01.

KMX

CarMax

$59.61

-1.15 (-1.89%)

SNAP

Snap

$18.08

-0.77 (-4.08%)

XOP

SPDR Oil Exploration and Production Fund

$32.61

1.18 (3.75%)

RH

RH

$50.74

1.25 (2.53%)

XLE

Energy Select Sector SPDR

$66.42

1.56 (2.41%)

CIT

CIT Group

$46.05

0.84 (1.86%)

  • 21

    Jun

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

  • 30

    Jun

  • 19

    Jul

KMX CarMax
$59.61

-1.15 (-1.89%)

05/18/17
05/18/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Progressive (PGR) upgraded to Hold from Sell at Deutsche Bank with analyst Joshua Shanker saying his concerns over the company's margins "are not longer apt" and that sees no catalyst to the downside. 2. Shake Shack (SHAK) upgraded to Outperform from Neutral at Wedbush with analyst Nick Setyan saying the valuation at current share levels is attractive given Shake Shack's "industry-leading growth trajectory. 3. CarMax (KMX) upgraded to Outperform from Neutral at Wedbush with analyst Seth Basham saying the company's CAF credit losses will probably rise less in 2017 than in 2016, reducing "the risk of a credit-driven blowout." 4. Bank of Montreal (BMO) upgraded to Buy from Neutral at Citi with analyst Ian Sealey citing the recent pullback in the shares of Canadian banks as he sees "strong" book value and dividend growth over the longer term. 5. BioLineRx (BLRX) upgraded to Buy from Hold at Maxim with analyst Jason Kolbert saying the company is now closer to being a pivotal company after announcing it will initiate a Phase 3 program for BL-8040 in stem cell mobilization later this year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/05/17
MSCN
04/05/17
NO CHANGE
MSCN
CarMax Q1 tracking 'very strong,' says MScience
MScience said CarMax's Q1 is "very strong" with same-store-sales tracking to +8-10% versus consensus of +5%.
05/18/17
WEDB
05/18/17
UPGRADE
WEDB
Outperform
CarMax upgraded to Outperform from Neutral at Wedbush
05/18/17
WEDB
05/18/17
UPGRADE
WEDB
Outperform
CarMax upgraded on credit improvement at Wedbush
As noted earlier, Wedbush upgraded CarMax to Outperform from Neutral. Analyst Seth Basham says that the company's CAF credit losses will probably rise less in 2017 than in 2016, reducing "the risk of a credit-driven blowout." He also believes that the company's core business will continue to be strong. Target to $70 from $60.
SNAP Snap
$18.08

-0.77 (-4.08%)

06/09/17
06/09/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Snap (SNAP) downgraded to Neutral from Buy at Citi with analyst Mark May saying a slower than expected roll-out of new platforms and channels like self-serve is slowing down the pace of monetization growth. 2. Domino's Pizza (DPZ) downgraded to Neutral from Buy at Longbow with analyst Alton Stump saying his checks indicate second quarter domestic franchised comparables are up 6.25%-6.75%, versus consensus of 7.4%, and recommends investors take a pause on putting new money to work given recent share strength. 3. Nordstrom (JWN) downgraded to Neutral from Buy at Guggenheim with analyst Michael Binetti saying he does not see much further upside potential, even in a leveraged buyout scenario. The analyst believes a going private buyer could only pay $46 per share to generate a 10% internal rate of return. 4. Cantel Medical (CMD) downgraded to Hold from Buy at Benchmark with analyst Raymond Myers saying that he is increasingly concerned that its comparisons become tougher in the next two quarters. 5. Endo (ENDP) downgraded to Hold following Opana ER removal from market at Stifel with analyst Annabel Samimy saying Endo's recovery "just got harder" following the FDA's request for the company to voluntarily remove Opana ER from the market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/09/17
SBSH
06/09/17
DOWNGRADE
Target $20
SBSH
Neutral
Snap downgraded to Neutral from Buy at Citi
Citi analyst Mark May downgraded Snap to Neutral and cut his price target for the shares to $20 from $24. The camera company closed yesterday down 4% to $18.85. A slower than expected roll-out of new platforms and channels like self-serve is slowing down the pace of monetization growth, May tells investors in a research note. Further, he believes investors "may continue to be wary near term" of the company's user growth, which disappointed in Q1. The analyst adds that the IPO lock-up expiration in August will increase the stock available for sale by over 500% or 949M shares. He believes this could pressure the stock.
06/08/17
OPCO
06/08/17
NO CHANGE
Target $23
OPCO
Outperform
Oppenheimer checks show slower adoption by new advertisers for Snap
Oppenheimer analyst Jason Helfstein says his recent channel checks indicate strong growth in existing advertiser spend for Snap, but slower adoption by new advertisers due to platform-specific video ads, limited 3P data and brand safety concerns for user-generated story ads. As a result, the analyst removed $5M from this Q2 revenue estimate to reflect slower than expected advertiser adoption and added the same amount to his Q4 estimate. He expects all of the new advertiser headwinds to be solved over time. Snap's full roll-out of a self-service ad manager in July should accelerate new advertiser adoption in the second half of 2017, Helfstein tells investors in a research note. He keeps an Outperform rating on the shares with a $23 price target.
06/07/17
NOMU
06/07/17
NO CHANGE
Target $14
NOMU
Reduce
Snap download trends deteriorated thus far in Q2, says Nomura Instinet
An analysis of app download data from SensorTower points to year-over-year deterioration in Snapchat download trends through the first two months of Q2, Nomura Instinet analyst Anthony DiClemente tells investors in an intraday research note titled "Snap Back Unlikely in 2Q." He points out that Facebook's (FB) Instagram downloads grew year-over-year in Q2, which the analyst believes suggests competitive pressures may be intensifying for Snap. For April and May, SensorTower has Snap worldwide downloads down 22%. DiClemente keeps a Reduce rating on the shares with a $14 price target. He lowered his 2017 earnings per share estimate for SNAP to ($3.24) from ($2.68) and revenue estimate to $842M from $953M. These estimates are well below the consensus. Snap in midday trading is down 73c to $19.63.
XOP SPDR Oil Exploration and Production Fund
$32.61

1.18 (3.75%)

RH RH
$50.74

1.25 (2.53%)

06/07/17
DBAB
06/07/17
NO CHANGE
Target $45
DBAB
Hold
RH price cuts create downside risk in 2017, says Deutsche Bank
Deutsche Bank analyst Adam Sindler believes RH has had to cut prices above expectations, which creates risk to the downside over the remainder of 2017. Risk going forward is weighted more towards the price per item and not the number of items themselves, Sindler tells investors in a research note. He keeps a Hold rating on RH with a $45 price target.
06/02/17
SBSH
06/02/17
NO CHANGE
SBSH
Buy
RH post-earnings selloff a buying opportunity, says Citi
Citi analyst Geoffrey Small recommends using the post-earnings selloff in shares of RH as a buying opportunity. The stock in premarket trading is down 20% to $45.70. The analyst views the quarter's underlying sales as strong and notes that share buybacks could drive upside to guidance.
06/02/17
BOFA
06/02/17
NO CHANGE
Target $64
BOFA
Buy
RH continued SKU optimization drives lower 2017 guidance, says BofA/Merrill
BofA/Merrill analyst Lorraine Hutchinson said RH's continued inventory optimization will increase sales and free cash flow but will limit and earnings rebound in 2017, resulting in lower 2017 earnings guidance. The analyst thinks most of the company-specific issues are behind the company and the real estate transformation and Modern remain compelling growth opportunities. Hutchinson maintains a Buy rating and $64 price target on RH shares.
06/02/17
KEYB
06/02/17
NO CHANGE
KEYB
RH outlook still positive, says KeyBanc
After RH provided Q2 EPS guidance that KeyBanc analyst Bradley Thomas finds "disappointing," he is "encouraged" by the company's comp sales, inventory reductions, the outlook for its new stores, and its potential for share repurchases. The analyst remains upbeat on the company's longer term outlook and keeps an Overweight rating on the shares.
XLE Energy Select Sector SPDR
$66.42

1.56 (2.41%)

CIT CIT Group
$46.05

0.84 (1.86%)

06/06/17
OPCO
06/06/17
NO CHANGE
Target $54
OPCO
Outperform
CIT Group remains 'compelling' value in banking, says Oppenheimer
Despite rising 22% since the announced sale of its commercial aircraft business on October 6, shares of CIT Group remains one of the most "compelling values" in the banking sector, Oppenheimer analyst Chris Kotowski tells investors in a research note. The stock remains "way too cheap" at around tangible book value, the analyst contends. He keeps an Outperform rating on CIT with a $54 price target.
04/26/17
BOFA
04/26/17
UPGRADE
BOFA
Buy
CIT Group upgraded to Buy, transitioning to a mid-size bank, says BofA/Merrill
BofA/Merrill analyst Derek Hewett upgraded CIT Group to Buy from Neutral and raised its price target to $54 from $44 saying its transition to a domestic mid-sized bank from a sub-scale global financial is nearly complete. The analyst believes CIT's improving earnings visibility and profitability are underappreciated and expects shares to lift as the market begins to value CIT more like a national middle-market bank. Hewett also believes management may explore other strategic alternatives given the more favorable operating backdrop and less complex structure.
04/04/17
BTIG
04/04/17
NO CHANGE
Target $45
BTIG
Buy
CIT more feasible takeout target after leasing sale, says BTIG
BTIG analyst Mark Palmer believes CIT Group is a "more feasible takeout target" following the sale of its aircraft leasing unit. With today's sale closing, CIT is now set to use the proceeds to fund approximately $3B in capital return and approximately $5.8B in redemptions of senior unsecured debt, Palmer tells investors in a research note. CIT management's stated intention to retain the company's "struggling" rail car leasing unit may reduce the field of potential bidders, however, the analyst adds. He reiterates a Buy rating on CIT with a $45 price target.
04/03/17
SPHN
04/03/17
NO CHANGE
Target $49
SPHN
Equal Weight
Economic positive to CIT if aircraft leasing sale falls through, says Stephens
Stephens analyst Vincent Cainti believes it would be an economic positive to CIT Group if the aircraft leasing sale fell through. Nonetheless, the analyst thinks CIT Group's sale of its aircraft lessor is still likely to close. He reiterates an Equal Weight rating and $49 price target on the shares.

TODAY'S FREE FLY STORIES

UUP

PowerShares DB US Dollar Index Up

$24.34

-0.07 (-0.29%)

06:30
11/20/17
11/20
06:30
11/20/17
06:30
Technical Analysis
PowerShares DB US Dollar Index Up: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UDN

PowerShares DB US Dollar Index Down

$22.13

0.07 (0.32%)

06:29
11/20/17
11/20
06:29
11/20/17
06:29
Technical Analysis
PowerShares DB US Dollar Index Down: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Wal-Mart

$97.47

-2.15 (-2.16%)

06:28
11/20/17
11/20
06:28
11/20/17
06:28
Downgrade
Wal-Mart rating change  »

Wal-Mart downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 20

    Feb

VZ

Verizon

$45.42

0.65 (1.45%)

06:27
11/20/17
11/20
06:27
11/20/17
06:27
Upgrade
Verizon rating change  »

Verizon upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MHK

Mohawk

$272.20

1.55 (0.57%)

06:24
11/20/17
11/20
06:24
11/20/17
06:24
Conference/Events
Mohawk management to meet with Evercore ISI »

Field trip to company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

VZ

Verizon

$45.42

0.65 (1.45%)

06:23
11/20/17
11/20
06:23
11/20/17
06:23
Periodicals
Verizon, NFL near deal for digital streaming rights, Bloomberg reports »

Verizon is nearing a deal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$55.83

0.58 (1.05%)

06:22
11/20/17
11/20
06:22
11/20/17
06:22
Conference/Events
Best Buy management to meet with Piper Jaffray »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

AMZN

Amazon.com

$1,129.88

-7.41 (-0.65%)

06:22
11/20/17
11/20
06:22
11/20/17
06:22
Periodicals
Jeffrey Tambor won't return to Amazon series 'Transparent,' Deadline reports »

Jeffrey Tambor has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

EYE

National Vision

$29.98

-0.15 (-0.50%)

06:22
11/20/17
11/20
06:22
11/20/17
06:22
Initiation
National Vision initiated  »

National Vision initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AAAP

Advanced Accelerator

$81.20

-0.04 (-0.05%)

, NVS

Novartis

$83.98

0.96 (1.16%)

06:20
11/20/17
11/20
06:20
11/20/17
06:20
Downgrade
Advanced Accelerator, Novartis rating change  »

Advanced Accelerator…

AAAP

Advanced Accelerator

$81.20

-0.04 (-0.05%)

NVS

Novartis

$83.98

0.96 (1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 04

    Dec

  • 06

    Dec

  • 09

    Dec

  • 26

    Jan

  • 17

    May

LYV

Live Nation

$45.34

-0.02 (-0.04%)

06:19
11/20/17
11/20
06:19
11/20/17
06:19
Downgrade
Live Nation rating change  »

Live Nation downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$170.15

-0.95 (-0.56%)

, INTC

Intel

$44.63

-1.02 (-2.23%)

06:18
11/20/17
11/20
06:18
11/20/17
06:18
Periodicals
KGI says Apple 2018 iPhones will feature faster basedband chips, 9to5Mac reports »

Apple's (AAPL) 2018…

AAPL

Apple

$170.15

-0.95 (-0.56%)

INTC

Intel

$44.63

-1.02 (-2.23%)

QCOM

Qualcomm

$66.72

0.61 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 06

    Mar

RHHBY

Roche

$29.10

0.205 (0.71%)

06:18
11/20/17
11/20
06:18
11/20/17
06:18
Hot Stocks
Breaking Hot Stocks news story on Roche »

Roche: Study showed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 23

    Dec

  • 23

    Feb

CATB

Catabasis Pharmaceuticals

$1.62

-0.03 (-1.82%)

06:17
11/20/17
11/20
06:17
11/20/17
06:17
Upgrade
Catabasis Pharmaceuticals rating change  »

Catabasis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

RHHBY

Roche

$29.10

0.205 (0.71%)

06:17
11/20/17
11/20
06:17
11/20/17
06:17
Hot Stocks
Roche: Phase III IMpower150 study met co-primary endpoint of PFS »

Roche announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 23

    Dec

  • 23

    Feb

DLPH

Delphi

$98.70

-0.54 (-0.54%)

06:14
11/20/17
11/20
06:14
11/20/17
06:14
Upgrade
Delphi rating change  »

Delphi upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 16

    Jan

TOSBF

Toshiba, also use TOSYY

$2.55

-0.014 (-0.55%)

, TOSYY

Toshiba, also use TOSBF

$15.20

-0.15 (-0.98%)

06:13
11/20/17
11/20
06:13
11/20/17
06:13
Hot Stocks
Toshiba to proceed with financing transaction to close on December 5 »

Toshiba Corporation, as…

TOSBF

Toshiba, also use TOSYY

$2.55

-0.014 (-0.55%)

TOSYY

Toshiba, also use TOSBF

$15.20

-0.15 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRVL

Marvell

$20.29

0.03 (0.15%)

, CAVM

Cavium

$75.83

-0.47 (-0.62%)

06:12
11/20/17
11/20
06:12
11/20/17
06:12
Periodicals
Marvell to acquire Cavium for $6B, Reuters reports »

Marvell Technology Group…

MRVL

Marvell

$20.29

0.03 (0.15%)

CAVM

Cavium

$75.83

-0.47 (-0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

GRPN

Groupon

$5.47

0.03 (0.55%)

06:12
11/20/17
11/20
06:12
11/20/17
06:12
Recommendations
Groupon analyst commentary  »

Groupon remains an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAH

Cardinal Health

$57.51

0.09 (0.16%)

06:11
11/20/17
11/20
06:11
11/20/17
06:11
Downgrade
Cardinal Health rating change  »

Cardinal Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 29

    Nov

  • 30

    Nov

TOSBF

Toshiba, also use TOSYY

$2.55

-0.014 (-0.55%)

, TOSYY

Toshiba, also use TOSBF

$15.20

-0.15 (-0.98%)

06:11
11/20/17
11/20
06:11
11/20/17
06:11
Hot Stocks
Toshiba to explore alternatives to sell Westinghouse related assets »

Toshiba Corporation…

TOSBF

Toshiba, also use TOSYY

$2.55

-0.014 (-0.55%)

TOSYY

Toshiba, also use TOSBF

$15.20

-0.15 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALE

Vale

$10.11

0.14 (1.40%)

06:10
11/20/17
11/20
06:10
11/20/17
06:10
Upgrade
Vale rating change  »

Vale upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDC

First Data

$16.73

-0.04 (-0.24%)

06:10
11/20/17
11/20
06:10
11/20/17
06:10
Upgrade
First Data rating change  »

First Data upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKU

BankUnited

$34.60

0.3 (0.87%)

06:10
11/20/17
11/20
06:10
11/20/17
06:10
Upgrade
BankUnited rating change  »

BankUnited upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCS

Barclays

$9.76

0.05 (0.51%)

06:10
11/20/17
11/20
06:10
11/20/17
06:10
Upgrade
Barclays rating change  »

Barclays upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.